Greenland Capital Management LP
Position in TEVA — Teva Pharmaceutical Industries Ltd
CIK 1896430
NEW YORK, NY
Position in TEVA
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$2,710,400
-$527,500 QoQ
Shares Held
80,000
-25.6% QoQ
Ownership
0.007%
of shares outstanding
% of Portfolio
0.61%
of 13F equity value
Holder Rank
#242
of 673 holders
Holding Since
Dec 2024
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TEVA Over Time
Shares Held
Position Value (USD)
Derivatives in TEVA
reported options exposure · as of Dec 31, 2024CallValue
$551,000
CallShares
25,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Greenland Capital Management LP holds $16,423,960 across 2 Drug Manufacturers - Specialty & Generic names. TEVA ranks #2 (16.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LQDA |
Liquidia Corp
|
172,000 | $13,713,560 | |
| 2 | TEVA |
Teva Pharmaceutical Industries Ltd
This page
|
80,000 | $2,710,400 |
All Filings in TEVA
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,710,400 | 80,000 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $3,237,900 | 107,500 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,542,335 | 113,500 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $2,546,149 | 126,047 | Shares | Sole | 2025-11-10 | |
| 2024-12-31 | $551,000 | 25,000 | Call | Sole | 2025-02-13 | |
| 2024-12-31 | $440,800 | 20,000 | Shares | Sole | 2025-02-13 | |
| No filing history on record for this holder in this stock. | ||||||